MPXI and Early Neutrophilia: New Potential Therapeutic Biomarkers for Recombinant Human Granulocyte Colony-stimulating Factor

Overview

Journal J Clin Lab Anal

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
Pathology

Date 1998 Mar 4

PMID 9484668

Citations 1

Authors

N Charuruks

N Voravud

V Sriuranpong

Affiliations

Soon will be listed here.

Abstract

We evaluated the effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) given after myelosuppressive chemotherapy in 15 cancer patients. No severe neutropenia (absolute neutrophil count, ANC < 0.5 x 10(3)/microL) was noticed in 10 rhG-CSF primary prophylactic patients, but was noticed in two of five rhG-CSF secondary prophylactic patients. Neutrophilia characterized by shift to the left occurred within 24 hours after starting rhG-CSF prophylaxis. Thereafter, conversion to normal level occurred within 24 hours. The peak of neutrophilia occurred earlier in the primary group than in the secondary prophylactic group. The detection of myeloperoxidase (MPO) using flow cytochemistry blood autoanalyzer (TechniconR H * 1) was evaluated as mean peroxidase index (MPXI). Leukocyte alkaline phosphatase (LAP) using the method of Kaplow (Am J Clin Pathol 39:439-449, 1963) was recorded as LAP score. There was a statistically significant elevation of MPXI in the primary group over the secondary prophylactic patients. The LAP activity was in normal range. There was a slightly decreased red blood cell (RBC) count, hemoglobin (Hb), and platelet count. In conclusion, rhG-CSF induced neutrophilia with efficient enzymatic activity. These findings demonstrate the value of rhG-CSF in patients receiving chemotherapy. MPXI and early neutrophilia may serve as a potential biomarker of therapeutic efficacy of rhG-CSF.

Citing Articles

Automated quantitation of circulating neutrophil and eosinophil activation in asthmatic patients.

Leckie M, Bryan S, Khan J, Dewar A, Aikman S, McGrath J Thorax. 2000; 55(6):471-7.

PMID: 10817795 PMC: 1745769. DOI: 10.1136/thorax.55.6.471.

References

Bodey G, Buckley M, SATHE Y, Freireich E . Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966; 64(2):328-40. DOI: 10.7326/0003-4819-64-2-328. View

Molineux G, Pojda Z, Dexter T . A comparison of hematopoiesis in normal and splenectomized mice treated with granulocyte colony-stimulating factor. Blood. 1990; 75(3):563-9. View

Teshima T, Shibuya T, Harada M, Akashi K, Taniguchi S, Okamura T . Granulocyte-macrophage colony-stimulating factor suppresses induction of neutrophil alkaline phosphatase synthesis by granulocyte colony-stimulating factor. Exp Hematol. 1990; 18(4):316-21. View

Metcalf D . Lineage commitment of hemopoietic progenitor cells in developing blast cell colonies: influence of colony-stimulating factors. Proc Natl Acad Sci U S A. 1991; 88(24):11310-4. PMC: 53124. DOI: 10.1073/pnas.88.24.11310. View

Tsushita K, Hotta T, Ichikawa A, Murate T, Saito H . Induction of neutrophil alkaline phosphatase gene expression by granulocyte colony-stimulating factor in chronic myelogenous leukemia. Int J Hematol. 1993; 57(1):45-52. View

Fulton R, Gasper P, Ogilvie G, Boone T, Dornsife R . Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis in normal cats. Exp Hematol. 1991; 19(8):759-67. View

Klebanoff S . Antimicrobial mechanisms in neutrophilic polymorphonuclear leukocytes. Semin Hematol. 1975; 12(2):117-42. View

Ross D, Bentley S . Evaluation of an automated hematology system (Technicon H-1). Arch Pathol Lab Med. 1986; 110(9):803-8. View

Sato N, Mori M, Oshimura M, Ueyama Y, Miwa T, OHSAWA N . Factor(s) responsible for the increase in alkaline phosphatase activity of postmitotic granulocytes from normal individuals and patients with chronic myeloid leukemia. Blood. 1982; 59(1):141-7. View

10.

LORD B, Molineux G, Pojda Z, Souza L, Mermod J, Dexter T . Myeloid cell kinetics in mice treated with recombinant interleukin-3, granulocyte colony-stimulating factor (CSF), or granulocyte-macrophage CSF in vivo. Blood. 1991; 77(10):2154-9. View

11.

Welte K, Bonilla M, Gillio A, Boone T, Potter G, GABRILOVE J . Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med. 1987; 165(4):941-8. PMC: 2188574. DOI: 10.1084/jem.165.4.941. View

12.

Pojda Z, Molineux G, Dexter T . Hemopoietic effects of short-term in vivo treatment of mice with various doses of rhG-CSF. Exp Hematol. 1990; 18(1):27-31. View

13.

Charuruks N, Krailadsiri P, Voravud N, Nitipaijit N, Srisink N, Settapiboon R . Changes in white blood cells and myeloperoxidase activity in rhG-CSF prophylactic patients receiving cytotoxic chemotherapy. J Med Assoc Thai. 1994; 77(8):426-33. View

14.

Woodward T, McNiece I, Witte P, Bender P, Crittenden R, Temeles D . Further studies on growth factor production by the TC-1 stromal cell line: pre-B stimulating activity. Blood. 1990; 75(11):2130-6. View

15.

Bonilla M, Gillio A, Ruggeiro M, Kernan N, Brochstein J, Abboud M . Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. N Engl J Med. 1989; 320(24):1574-80. DOI: 10.1056/NEJM198906153202402. View

16.

Frei 3rd E, Canellos G . Dose: a critical factor in cancer chemotherapy. Am J Med. 1980; 69(4):585-94. DOI: 10.1016/0002-9343(80)90472-6. View

17.

Bronchud M, Scarffe J, Thatcher N, Crowther D, Souza L, Alton N . Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer. 1987; 56(6):809-13. PMC: 2002403. DOI: 10.1038/bjc.1987.295. View

18.

Sato N, Takatani O, Koeffler H, Sato H, Asano S, Takaku F . Modulation by retinoids and interferons of alkaline phosphatase activity in granulocytes induced by granulocyte colony-stimulating factor. Exp Hematol. 1989; 17(3):258-62. View

19.

Pizzo P . Granulocytopenia and cancer therapy. Past problems, current solutions, future challenges. Cancer. 1984; 54(11 Suppl):2649-61. DOI: 10.1002/1097-0142(19841201)54:2+<2649::aid-cncr2820541409>3.0.co;2-6. View

20.

. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol. 1994; 12(11):2471-508. DOI: 10.1200/JCO.1994.12.11.2471. View